Sam Brusco, Associate Editor05.05.22
Abbott has received U.S. Food and Drug Administration (FDA) clearance for its Alinity m STI assay, which detects and differentiates four common sexually transmitted infections (STIs). The first-of-its kind multiplex test will help address increasing STI rates.
The test to identify Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and Mycoplasma genitalium (MG) takes one swab or urine sample collected in a healthcare setting by either a clinician or the patient.
"Over the past several years, STI cases have been on the rise, and we expect to see increasing rates as people resume testing after delaying during the pandemic," Kathryn Becker, Ph.D., global director of scientific affairs innovation in Abbott's diagnostics business told the press. "With that comes an increased need for effective and efficient testing. This four-plex STI test gives healthcare providers a more holistic picture of someone's health in a single test, helping to support the best treatment plan to address these common STIs individually or as co-infections."
The pandemic boosted demand for additional healthcare delivery channels, particularly improving diagnostic testing quality and accessibility.
"The pandemic showed us the value of having aspects of testing available to people in their homes," said Becker. "As we look to the future of testing, we will be focused on bringing that kind of convenience and discretion for STIs and other conditions."
The test to identify Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and Mycoplasma genitalium (MG) takes one swab or urine sample collected in a healthcare setting by either a clinician or the patient.
"Over the past several years, STI cases have been on the rise, and we expect to see increasing rates as people resume testing after delaying during the pandemic," Kathryn Becker, Ph.D., global director of scientific affairs innovation in Abbott's diagnostics business told the press. "With that comes an increased need for effective and efficient testing. This four-plex STI test gives healthcare providers a more holistic picture of someone's health in a single test, helping to support the best treatment plan to address these common STIs individually or as co-infections."
The pandemic boosted demand for additional healthcare delivery channels, particularly improving diagnostic testing quality and accessibility.
"The pandemic showed us the value of having aspects of testing available to people in their homes," said Becker. "As we look to the future of testing, we will be focused on bringing that kind of convenience and discretion for STIs and other conditions."